125 related articles for article (PubMed ID: 8845858)
1. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness.
Steen VM; Gulbrandsen AK; Eiken HG; Berle JO
Pharmacogenetics; 1996 Feb; 6(1):113-6. PubMed ID: 8845858
[No Abstract] [Full Text] [Related]
2. A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients.
Sjøholt G; Gulbrandsen AK; Løvlie R; Berle JO; Molven A; Steen VM
Mol Psychiatry; 2000 Mar; 5(2):172-80. PubMed ID: 10822345
[TBL] [Abstract][Full Text] [Related]
3. Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment.
Dimitrova A; Milanova V; Krastev S; Nikolov I; Toncheva D; Owen MJ; Kirov G
Pharmacogenomics J; 2005; 5(1):35-41. PubMed ID: 15505643
[TBL] [Abstract][Full Text] [Related]
4. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder.
Sjøholt G; Ebstein RP; Lie RT; Berle JØ; Mallet J; Deleuze JF; Levinson DF; Laurent C; Mujahed M; Bannoura I; Murad I; Molven A; Steen VM
Mol Psychiatry; 2004 Jun; 9(6):621-9. PubMed ID: 14699425
[TBL] [Abstract][Full Text] [Related]
5. Genomic structure and chromosomal localization of a human myo-inositol monophosphatase gene (IMPA).
Sjøholt G; Molven A; Løvlie R; Wilcox A; Sikela JM; Steen VM
Genomics; 1997 Oct; 45(1):113-22. PubMed ID: 9339367
[TBL] [Abstract][Full Text] [Related]
6. Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy.
Shamir A; Ebstein RP; Nemanov L; Zohar A; Belmaker RH; Agam G
Mol Psychiatry; 1998 Nov; 3(6):481-2. PubMed ID: 9857972
[No Abstract] [Full Text] [Related]
7. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness.
Steen VM; Løvlie R; Osher Y; Belmaker RH; Berle JO; Gulbrandsen AK
Pharmacogenetics; 1998 Jun; 8(3):259-68. PubMed ID: 9682271
[TBL] [Abstract][Full Text] [Related]
8. Genomic structure and novel variants of myo-inositol monophosphatase 2 (IMPA2).
Yoshikawa T; Padigaru M; Karkera JD; Sharma M; Berrettini WH; Esterling LE; Detera-Wadleigh SD
Mol Psychiatry; 2000 Mar; 5(2):165-71. PubMed ID: 10822344
[TBL] [Abstract][Full Text] [Related]
9. Genomic structure and sequence analysis of a human inositol polyphosphate 1-phosphatase gene (INPP1).
Løvlie R; Gulbrandsen AK; Molven A; Steen VM
Pharmacogenetics; 1999 Aug; 9(4):517-28. PubMed ID: 10780272
[TBL] [Abstract][Full Text] [Related]
10. Structure of inositol monophosphatase, the putative target of lithium therapy.
Bone R; Springer JP; Atack JR
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10031-5. PubMed ID: 1332026
[TBL] [Abstract][Full Text] [Related]
11. A novel human myo-inositol monophosphatase gene, IMP.18p, maps to a susceptibility region for bipolar disorder.
Yoshikawa T; Turner G; Esterling LE; Sanders AR; Detera-Wadleigh SD
Mol Psychiatry; 1997 Sep; 2(5):393-7. PubMed ID: 9322233
[TBL] [Abstract][Full Text] [Related]
12. Stereochemistry at phosphorus of the reaction catalyzed by myo-inositol monophosphatase.
Fauroux CM; Lee M; Cullis PM; Douglas KT; Gore MG; Freeman S
J Med Chem; 2002 Mar; 45(6):1363-73. PubMed ID: 11882005
[TBL] [Abstract][Full Text] [Related]
13. Inositol-1-phosphatase in red blood cells of manic-depressive patients before and during treatment with lithium.
Moscovich DG; Belmaker RH; Agam G; Livne A
Biol Psychiatry; 1990 Mar; 27(5):552-5. PubMed ID: 2155674
[No Abstract] [Full Text] [Related]
14. Increased inositol-monophosphatase activity by lithium treatment in bipolar patients.
Kaya N; Resmi H; Ozerdem A; Guner G; Tunca Z
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):521-7. PubMed ID: 15093960
[TBL] [Abstract][Full Text] [Related]
15. Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression.
Kofman O; Belmaker RH
Biol Psychiatry; 1993 Dec; 34(12):839-52. PubMed ID: 8110911
[TBL] [Abstract][Full Text] [Related]
16. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness.
Moore GJ; Bebchuk JM; Parrish JK; Faulk MW; Arfken CL; Strahl-Bevacqua J; Manji HK
Am J Psychiatry; 1999 Dec; 156(12):1902-8. PubMed ID: 10588403
[TBL] [Abstract][Full Text] [Related]
17. Association analysis between polymorphisms in the myo-inositol monophosphatase 2 (IMPA2) gene and bipolar disorder.
Bloch PJ; Weller AE; Doyle GA; Ferraro TN; Berrettini WH; Hodge R; Lohoff FW
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1515-9. PubMed ID: 20800640
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of coding and untranslated regions of rat cortex lithium-sensitive myo-inositol monophosphatase cDNA.
Parthasarathy L; Parthasarathy R; Vadnal R
Gene; 1997 May; 191(1):81-7. PubMed ID: 9210592
[TBL] [Abstract][Full Text] [Related]
19. Lithium therapy in the treatment of manic-depressive illness. Present status and future perspectives. A critical review.
Emilien G; Maloteaux JM; Seghers A; Charles G
Arch Int Pharmacodyn Ther; 1995; 330(3):251-78. PubMed ID: 8836446
[TBL] [Abstract][Full Text] [Related]
20. A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription.
Ohnishi T; Yamada K; Ohba H; Iwayama Y; Toyota T; Hattori E; Inada T; Kunugi H; Tatsumi M; Ozaki N; Iwata N; Sakamoto K; Iijima Y; Iwata Y; Tsuchiya KJ; Sugihara G; Nanko S; Osumi N; Detera-Wadleigh SD; Kato T; Yoshikawa T
Neuropsychopharmacology; 2007 Aug; 32(8):1727-37. PubMed ID: 17251911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
